Wolff-Parkinson-White syndrome drug prophylaxis
Jump to navigation
Jump to search
|
Wolff-Parkinson-White syndrome Microchapters |
|
Differentiating Wolff-Parkinson-White syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wolff-Parkinson-White syndrome drug prophylaxis On the Web |
|
Risk calculators and risk factors for Wolff-Parkinson-White syndrome drug prophylaxis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]
Overview
Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients without preexcitation in resting ECG. Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease.
Drug Prophylaxis In The Patient With Proven Tachyarrhythmias
- Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients with out preexcitation in resting ECG.
- Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease.[1]
References
- ↑ Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.